Company news
Vertex Pharmaceuticals Incorporated news in 2005
Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2005, newest first.
GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir
December 16, 2005
FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
December 8, 2005
Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
December 7, 2005
Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
December 5, 2005
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $95.0 Million of its Convertible Senior Subordinated Notes Due 2011
November 28, 2005
AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor
November 11, 2005
Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX- 950 Presentations at the Upcoming AASLD Meeting
November 9, 2005
Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
October 31, 2005
Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
October 26, 2005
Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis
October 4, 2005
New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track
October 3, 2005
Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock
September 9, 2005
Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results
July 27, 2005